Calmino enters 2026 as market leader – PROIBS® was Sweden’s No. 1 IBS product in 2025
Gothenburg, Sweden – Calmino group AB begins 2026 with a significant strategic milestone. According to sales data from IQVIA, PROIBS® was the best-selling IBS product in Swedish pharmacies during the full year 2025, positioning PROIBS® as the No. 1 product within the IBS segment in Sweden.
IBS is one of the most common functional gastrointestinal disorders (Disorders of Gut-Brain Interaction), affecting up to15 percent of the population. People living with IBS experience symptoms during a substantial part of each month, often resulting in reduced quality of life and increased absence from work or studies. The strong demand for PROIBS® throughout 2025 reflects the need for effective and accessible self-care solutions for this patient group. In Sweden, the product is marketed by Nordic Drugs AB.
CEO Statement
“Achieving a market-leading position within IBS after 15 years on the Swedish pharmacy market clearly demonstrates the value of long-term, science-driven product development. Fora smaller company like Calmino group AB, this represents a strong commercial and strategic breakthrough in a highly competitive segment,”
“As a research-driven company, we are deeply grateful for the long-standing collaborations that have made this journey possible. This success reflects the close interplay between scientific research, clinical expertise and careful commercial execution. I would like to express my sincere appreciation to the researchers at Sahlgrenska University Hospital, the University of Gothenburg and Chalmers University of Technology for their invaluable scientific support over many years. I would also like to thank Nordic Drugs for their excellent work in bringing PROIBS® to patients in Sweden.” says Tobias Kisker, CEO of Calmino group AB.
PROIBS® – Swedish science with a proven global footprint
PROIBS<sup>®</sup> was developed by Calmino group AB in close collaboration with Sahlgrenska University Hospital and the University of Gothenburg and was first launched on the Swedish pharmacy market in 2010. The product is based on AVH200<sup>®</sup>, a proprietary herbal extract specifically developed to relieve IBS-related symptoms. Since its introduction, PROIBS® has expanded well beyond Sweden and is today available in 15 markets worldwide, reflecting broad international acceptance and long-term confidence in the product. Every month, PROIBS® is used by tens of thousands of consumers globally.
Attachments
Attached you will find high-resolution images (original resolution, suitable for print). All images may be used for editorial purposes in connection with coverage of Calmino.
About Calmino group AB
Founded in 2003, Calmino group AB is a science-driven Swedish healthcare company specializing in gut health. Headquartered at Sahlgrenska Science Park in Gothenburg, the company has more than 20 years of experience and works with long-term research, product development and international expansion.
Press contact & Media material
Tobias Kisker
CEO, Calmino group AB
tobias.kisker@calmino.com
Fredrik Larsson
Product Manager, Calmino group AB
fredrik.larsson@calmino.com
+46 (0)31 40 72 50
This claim has been approved in accordance with IQVIA’s guidelines for data sharing in marketing communications. Certificate available upon request.
